CLEOPATRA - Roche's pertuzumab to queen it over HER2 breast cancer?
This article was originally published in Scrip
Executive Summary
Roche will make global regulatory filings for its novel HER2-targeting anticancer pertuzumab by the end of the year on the basis of new data from the CLEOPATRA study. The pivotal Phase III trial met its primary endpoint of progression-free survival, top-line data announced today show.